Syndax Pharmaceuticals (SNDX) Other financing activities (2015 - 2026)

Syndax Pharmaceuticals' Other financing activities history runs 12 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• In Q1 2026, Other financing activities rose 1268.81% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 333.26% YoY), while the FY2025 annual figure was $1.5 million, down 10.32% from the prior year.
• Other financing activities for Q1 2026 stood at $7.5 million, up from -$5.3 million in the prior quarter.
• The five-year high for Other financing activities was $7.5 million in Q1 2026, with the low at -$5.3 million in Q4 2025.
• The 5-year median for Other financing activities is $545000.0 (2025), against an average of $1.6 million.
• The sharpest annual moves came in 2022 and 2025: Other financing activities surged 7337.37% in 2022, then plunged 934.07% in 2025.
• Syndax Pharmaceuticals' Other financing activities stood at $1.4 million in 2022, then tumbled by 92.21% to $112000.0 in 2023, then surged by 466.07% to $634000.0 in 2024, then slumped by 934.07% to -$5.3 million in 2025, then soared by 241.07% to $7.5 million in 2026.
• Business Quant data shows SNDX's Other financing activities at $7.5 million in Q1 2026, -$5.3 million in Q4 2025, and $6.4 million in Q3 2025.